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Glycans decorating cell surface and secreted proteins and lipids occupy the juncture where
critical host–host and host-pathogen interactions occur.The role of glycan epitopes in cell–
cell and cell-pathogen adhesive events is already well-established, and cell surface glycan
structures change rapidly in response to stimulus and inflammatory cues. Despite the wide
acceptance that glycans are centrally implicated in immunity, exactly how glycans and their
changes contribute to the overall immune response remains poorly defined. Sialic acids
are unique sugars that usually occupy the terminal position of the glycan chains and may
be modified by external factors, such as pathogens, or upon specific physiological cellular
events. At cell surface, sialic acid-modified structures form the key fundamental determi-
nants for a number of receptors with known involvement in cellular adhesiveness and cell
trafficking, such as the Selectins and the Siglec families of carbohydrate recognizing recep-
tors. Dendritic cells (DCs) preside over the transition from innate to the adaptive immune
repertoires, and no other cell has such relevant role in antigen screening, uptake, and its
presentation to lymphocytes, ultimately triggering the adaptive immune response. Interest-
ingly, sialic acid-modified structures are involved in all DC functions, such as antigen uptake,
DC migration, and capacity to prime T cell responses. Sialic acid content changes along
DC differentiation and activation and, while, not yet fully understood, these changes have
important implications in DC functions. This review focuses on the developmental regula-
tion of DC surface sialic acids and how manipulation of DC surface sialic acids can affect
immune-critical DC functions by altering antigen endocytosis, pathogen and tumor cell
recognition, cell recruitment, and capacity for T cell priming. The existing evidence points
to a potential of DC surface sialylation as a therapeutic target to improve and diversify
DC-based therapies.
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INTRODUCTION
Immunological studies, nowadays, imply researchers have at least
basic knowledge of glycobiology since, at some point of their study,
researchers are faced with glycosylation-related features. Glyco-
sylation is a post-translational modification of basically all the
secreted and cell surface proteins, as well as of lipids. Thus, all
contacts between cell surface and/or serum molecules are con-
tinuously accompanied by glycosylation. The immune response
lays on innumerous contacts between cells and molecules, a good
example being the case of immunological synapses, a junction
that forms between T cells and specialized cells and the antigen-
antibody interactions. All the immune encounters have, with great
probability, glycans occupying, and influencing the juncture. Thus,
all self-asserted immunologist should consider to be (at least
partially) glycobiologists.
Among the several cell types that constitute the immune system,
dendritic cells (DCs) are key players. DCs survey the microen-
vironment where they are positioned in order to help correctly
classify collected antigen information, in a “self” or “‘foreign” cate-
gory, and to respond accordingly. They carry antigen information
from the infection site to the secondary lymphatic organs, pre-
senting them to T cells, strongly potentiating a specific immune
response against pathogens (Figure 1). The immune response
is thus tremendously dependent on DCs and impairment of
DC functions, as studied using animal models deficient for DC
function-related molecules, or absence of DC populations, have
been associated with infection or, oppositely, to a wide range of
autoimmune diseases (1). DCs also play an important role in anti-
tumoral immunity, whereupon specific cytotoxic T cells may be
primed by DCs to respond against tumor cells. Investigating the
underlying mechanisms of DC-pathogen or DC-host and -tumor
cell interactions may help us to better comprehend the immune
response in physiological and pathological events and to identify
new targets for therapeutic intervention.
Dendritic cells show specific glycan patterns at cell surface,
which are modulated during cell differentiation and respond to
stimuli such as inflammatory cytokines and pathogens (2–4).
Sialic acid is a sugar that frequently terminates glycan struc-
tures. Due to its terminal position and properties, sialic acid
can mediate many immune processes such as host-pathogen
recognition, migration, and antigen presentation, among other
non-immune related processes. The addition of this sugar is
mediated by a number of enzymes, the sialyltransferases, mainly
located in the Golgi apparatus. Sialyltransferase expression is
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FIGURE 1 | Dendritic cell (DC) immune functions. DCs act on three main
events: the antigen capture after interaction with host cells, microbial agents,
and tumor cells by recognizing Pathogen-Associated Molecular Patterns
(PAMPs) and self molecules through Pathogen Recognition Receptors (PRRs)
and other cell surface receptors like Siglecs or C-type Lectins (CLRs);
maturation and migration toward the secondary lymphoid organs; T cell
activation where DCs present the processed antigens to T cells eliciting a
specific and enduring response or tolerance from T cells.
finely regulated during DC differentiation and maturation, con-
curring with the expression of sialylated structures (3, 4). In
diverse immune events, the sialylated glycans will be recognized
by lectins, i.e., carbohydrate-binding proteins that are expressed
in other cells or by DCs. While promoting cell recognition by
some lectins, the presence of specific sialic acids can actually
switch off recognition by other lectins specific for asialylated gly-
cans. Thus, glycan recognition by DC lectins may impact the DC
immunobiological functions. Thus, a deeper understanding of
sialic acid’s influence in the DC immunobiology potentially leads
to a better understanding of the immune mechanisms mediated
by DCs.
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This review will focus on DC’s glycoimmune processes, with
special attention to the sialic acid-mediated ones and how they
modulate the different DC functions. It includes an introduction
of DCs’ function and glycan recognition receptors, following a
description of processes known to be mediated by sialic acid such
as endocytosis, migration, priming of adaptive immune response,
and pathogen/tumoral recognition.
DENDRITIC CELLS
Dendritic cells are part of the innate response and are essential to
boost and/or regulate the adaptive immune response. They cap-
ture antigens in an earlier phase, process them “on the go” while
migrating toward secondary lymphoid organs, such as lymph
nodes, where they present, via major histocompatibility complex
(MHC), the processed antigens to T cells and thus enacting an
adaptive immune response. DCs can also present antigens to B
cells, although by non-classical (non-MHC) mechanisms (5–7).
Phenotypically, DCs are a heterogeneous population with differ-
ent cell subsets, populating various organs. They can be broadly
classified according the inflammatory status and differentiation
state. Accordingly, conventional DCs are seen in a steady-state,
that is, in the absence of infection and inflammation, and they can
functionally be divided in two major types: migratory and non-
migratory (lymphoid-tissue-resident) DCs [reviewed by Short-
man and Naik (8)]. A good example of the former are dermal
DCs and Langerhans cells that mainly reside in skin tissues and
after antigen contact, they mature and migrate to the draining
lymph nodes – hence the “migratory” classification. Conven-
tional, non-migratory DCs (like spleen DCs) reside in secondary
lymphoid organs, where they constantly screen blood or lymph
for pathogens. The variety of DCs inside both these groups is
significant and adapted toward the tissue where they reside in
the immature state. Regarding DC differentiation, both canoni-
cal myeloid and lymphoid hematopoietic progenitors contribute
to the steady-state DC pool and, actually, DCs use unique and
flexible developmental programs that cannot be categorized into
the conventional myeloid or lymphoid pathway. The expression
of the Fms-like tyrosine kinase 3 (Flt-3) molecules is character-
istic of DC precursors, regardless of the myeloid or lymphoid
lineage and DCs development is driven by Flt3-ligand (Flt3L)
(8–14). Much interestingly, it was recently reported that con-
ventional DCs are marked by the exclusive expression of the
DNGR-1 (15).
Opposed to the conventional DCs, some populations are
inflammatory or infection-derived DCs. These populations
include the plasmacytoid DC (pDC) population, a first line of
defense against microbial invasion. Functionally specialized in the
detection of viral infections, pDCs, develop a fully differentiated
DC phenotype after infection and secretion of type 1 interferon
(16, 17). Other inflammatory DCs include the monocyte-derived
DCs (moDCs), comprising the TNF-α, inducible nitrous oxide
synthase-producing DCs (Tip-DCs), a pathogenic subpopulation
generated in an infection context (non-steady-state) [reviewed in
Ref. (18)].
Dendritic cells constitutively uptake antigens in its surround-
ings as a surveillance measure (typical of the steady-state), funda-
mental to rapidly trigger the adaptive response against pathogens
(inflammation) (19). DCs are, thus, naturally equipped with dis-
tinct means to uptake antigens, including: (1) receptor-mediated
endocytosis, on which particles are endocytosed after cell surface
receptor recognition; (2) macropinocytosis, or the non-selective
endocytosis of solutes, a process constitutive in DCs and the
major source of antigens for DC presentation (20); and (3) phago-
cytosis, the uptake of large molecules or cells, including virus,
bacteria, protein clusters, apoptotic, and necrotic cells, which also
involves specific membrane receptors. The uptake of foreign anti-
gens usually trigger activation signals that will lead DCs to a mature
phenotype, on which all the potential for antigen presentation and
stimulation of the adaptive response immune cells is maximized.
Endocytosis is also fundamental in the maintenance of the self-
tolerance mechanisms since, at steady-state, self-antigens are nor-
mally endocytosed and posteriorly presented by DCs. Endocytosis
of self-antigens does not usually induces significant maturation
changes (21), thus contributing to turn DCs tolerogenic and pro-
moting regulatory but not effector T cells. Nevertheless, it has been
suggested that the presence of very small, time-persistent concen-
trations of foreign and more common antigens are responsible for
the induction of tolerance to those same antigens. These tolerance-
inducing antigens are expressed by microorganisms present dur-
ing the development of the immune system, such as commensal
bacteria, flora members, and helminthes. The knowledge about
these mechanisms raised the hypothesis that common microor-
ganisms are able to regulate the immune system, the “old friends”
hypothesis (22–24). These time-persistent antigens, thus shape
our immune system to its present state, being presently not only
tolerated but, in fact, needed in order to maintain the general
tolerance balance. The “old friend” hypothesis complements the
“hygiene”hypothesis stating, in brief, that the lack of immune chal-
lengers due to excessive hygiene is related to the growing number
of autoimmune and hypersensitivity diseases that is observed in
the developed countries, and not in the developing ones (24). Due
to its key role in antigen uptake and presentation, DCs too may be
involved in this mechanism of tolerance-induction toward these
“old friends.”
Dendritic cell maturation is the sum of all the phenotypical and
functional changes occurring upon encounter with immune stim-
uli (i.e., antigens, cytokines, etc.) and it is crucial to enable DCs
to effectively activate T cells. It is characterized by rapid downreg-
ulation of the antigen uptake process, acidification of lysossomal
compartments, higher expression of MHC II molecules and of
CD80 and CD86 co-stimulatory molecules, de novo or upregu-
lated synthesis of DC-specific inflammatory cytokines (25). All
these maturation and migration-changes are necessary hallmarks
to enable DCs to perform antigen presentation and boosting T and
B cell responses (26). It is also known that the molecular nature
of uptaken antigens, as well as the cytokines to which DCs are
exposed during the uptake process, are responsible for the mod-
ulation of the maturation process. This ultimately influences the
differentiation of the DC-pulsed T cells into functionally distinct
subtypes, namely, T helper type 1 or 2 (Th1 or Th2), T helper 17
(Th17), or regulatory (Treg) cells, actively shaping a future active
or tolerance response.
The migration (or homing) of conventional or inflammatory
DCs loaded with antigens to T cell niches (normally, secondary
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lymphatic organs) is a crucial step for the setting of effective
immune responses. This process is characterized by chemokine-
mediated cell recruitment to the lymphoid target site and, activa-
tion of the surrounding tissues (27–29). Tissue activation helps
to increase the cell adhesion to the endothelium, by inducing the
expression of several adhesion molecules, of which integrins and
selectins and its ligands are the most relevant elements.
From all the above observations, it is, thus, clear and generally
accepted that DC functions rely on a complex set of mecha-
nisms that involve DC differentiation, ontogeny, maturation, and
permanent contacts with other cells and pathogens.
PATHOGEN RECOGNITION BY DENDRITIC CELLS
Pathogen recognition by DCs depends on the identification of
distinct microbial patterns, not present in mammalian cells, but
shared by most of the pathogenic microbial, known as “pathogen-
associated molecular patterns” (PAMPs) (30, 31). They include
bacterial and viral unmethylated CpG DNA, bacterial flagellin,
peptides containing N -formylmethionine residues, lipoteichoic
acids, and double-stranded and single-stranded viral RNA. A
substantial part of PAMPs are glycan-containing ones, such as
lipopolysaccharide (LPS), N -acetylglucosamine, peptidoglycan,
and terminal fructose- and mannose-containing glycans, and
glucan-containing cell walls from fungi.
Pathogen-associated molecular patterns are recognized by spe-
cific receptors named “pattern recognition receptors” (PRRs),
with functions aggregating endocytosis and intracellular signaling.
Examples of PRRs expressed by DCs include Scavenger receptors,
Nod-like receptors, and C-type lectins (CLRs). However, perhaps,
the most widely studied are the Toll-like receptors (TLRs), a grow-
ing family of 12 evolutionary conserved PRRs consisting of type 1
integral membrane glycoprotein with relevant role in the micro-
bial response. The outcome of TLR recognition is the induction
of intracellular signaling and consequent expression of antigen
presentation molecules (MHC II molecules), co-stimulatory mol-
ecules (CD80/86, CD40), inflammatory and/or antiviral cytokines
(such as TNF-α, IL-12, IL-23, IFNα/β), chemokines (i.e., IL-8,
RANTES) (32, 33), thus enacting a powerful response against
pathogenic microbes.
C-type lectins are another very relevant family of PRRs
expressed by DCs (34). Being lectins, their main function is
to recognize glycan structures and, in immunological context,
they recognize pathogen-associated glycans or glycosylated self-
antigens. In DCs, some CLRs of note include the DC-Specific
Intracellular adhesion molecule-3 Grabbing Non-integrin (DC-
SIGN), CD207/Langerin, the Selectin family (discussed below),
the Macrophage Galactose/N -acetylgalactosamine-specific Lectin
(MGL-1), Mannose Receptor (MR), DEC205, the Blood DC anti-
gens 2 (BDCA 2), the Dendritic Cell Immunoreceptor (DCIR), the
Dendritic Cell Immunoactivating receptor (DCAR), and Dectin-
1/2/3. In contrast to TLRs, all of these CLRs functionally bind gly-
can structures expressed by mammalian cells (except for Dectin-
1/2/3 that apparently only recognizes fungal and/or mycobacterial
glycans), a fact demonstrating its potential role in both host and
pathogen recognition (35). CLRs can also recognize and internal-
ize pathogens for presentation without inducing DCs’ maturation.
In fact, the CLR-mediated antigen uptake doesn’t necessarily elicit
a factual immune response, and may instead contribute to induce
immunological tolerance (36). A downside of these phenomena
is the potential immune escape of pathogens recognized via CLRs
(35, 37–39).
Like CLRs, the Sialic acid-binding immunoglobulin-like lectins
(Siglecs) can also recognize pathogens’ glycoproteins and glycol-
ipids thus also contributing to the host’s innate immune responses.
Siglecs specifically recognize sialic acid-containing glycans and as
mentioned below they also play a relevant role in self recognition
(40–43). The biological and immunological relevance of CLR and
Siglec receptors will be discussed in detail in later sections.
Dendritic cells can also recognize and internalize microbes
and its derivate particles by receptors that bind to opsonins in
opsonized (“coated”) microbes. Opsonization of microbes can
occur in two forms: by coating with complement proteins or by
binding of antibodies to antigens expressed on their surface. DC
recognition of opsonized microbes is thus mainly mediated by
complement receptors and Fc receptors and assures the capture
of pathogens that might otherwise evade recognition by other DC
receptors (44, 45).
Summarizing, DCs can interact in different ways with microbes,
as well as with the host antigens, through panoply of receptors.
This recognition initiate mechanisms that will induce or suppress a
specific immune response. The DC recognition is thus considered
to be of great relevance for the development of a suitable, specific
immune outcome, dictating the balance tolerance/reactivity of the
developing host-pathogen response.
DENDRITIC CELLS-BASED THERAPY
The current knowledge of DC immunobiology allowed sev-
eral biotechnological and pharmaceutical companies to develop
DC-based immunotherapies. Applications for DC-based therapy
include a plethora of pathologies ranging from infectious and
hypersensitivity diseases to malignancies. One strategy is the ex
vivo upload of DCs with the antigen to turn them able to effi-
ciently develop an efficient response against the antigen bearer
(46–50). The best example of this strategy is the vaccination of
cancer patients with DCs loaded with tumor antigens.
Other approaches include the use of specific antibodies tar-
geting DC endocytic receptors that are used to force the upload
of specific antigens toward that receptor. Antibodies are also
used to block specific receptor-ligand interaction and consequent
downstream signaling, counteracting for instance the negative
immunomodulatory cues of the tumor microenvironment.
Dendritic cells have also been studied as targets of DNA vac-
cines encoding for antigens (51). Viral transduction not only
targets antigens to DCs, but also induces intracellular pathways
to modulate the immune response (52).
All these relatively recent drug-niche that exploits DC unique
immune potential is proof of reconnaissance of DCs’ cornerstone
role in the immune system. Nevertheless, the DC-based therapies
still face several hindrances to full application, mostly derived from
the lack of full knowledge regarding pathogenesis/tolerance bal-
ance mechanisms, an area where glycosylation has been shown to
have a relevant role.
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GLYCOSYLATION AND SIALYLATION
Glycosylation is the most frequent modification of proteins and
lipids. The majority of glycans exist as membrane-bound or sol-
uble glycoconjugates. One consequence of this fact is that all
cells present at their surface a glycocalyx, that is, the full surface-
complex of glycans, glycoproteins, and glycosylated lipids. The
three main classes of glycoconjugates are glycoproteins, proteo-
glycans, and glycolipids and their synthesis occurs mainly in (but
not limited to) the lumen of the endoplasmic reticulum and in
the Golgi apparatus. In glycoproteins, the sugar chain is clas-
sified as N - or O-linked, depending if the glycosidic moiety is
linked to an asparagine (Asn) residue in the protein moiety or to
a serine/threonine (Ser/Thr) residue, respectively.
The cell glycocalyx is the result of many factors. The most
relevant one is probably the expression of the set of enzymes
responsible for the synthesis and/or transfer of glycosylated struc-
tures, i.e., the glycosyltransferases. Also critical is the expression
of enzymes responsible for the removal of glycans or entire struc-
tures from glycosylated molecules, i.e., the glycosidases. These two
sets of enzymes work in a finely controlled balance both during
the glycoconjugate synthesis at the Golgi apparatus. Both enzyme
types can also be present in plasma membrane or soluble forms,
with potentially relevant biological roles as we shall see in sections
below (53–56).
Sialic acids are a large family of negatively charged, nine-
carbon monosaccharides that are normally found at gly-
can terminal positions. They include N -acetylneuraminic acid
(Neu5Ac), N -glycolylneuraminic acid (Neu5Gc), and 9-O-acetyl-
N -acetylneuraminic acid (9-O-Ac-NeuAc). Human cells can only
synthesize Neu5Ac. However, Neu5Gc can also be found in
some tumor cells (57). Interestingly, some pathogens may express
Neu5Ac, but Neu5Gc has never been reported to be synthesized
by any pathogenic bacteria (58). This review will focus mainly on
Neu5Ac and, for the sake of simplification, and we will strictly
refer to Neu5Ac when using the term “sialic acids.”
Sialyltransferases are a family of twenty glycosyltransferases
that catalyze the addition of sialic acids to terminal non-reducing
position of the oligosaccharide, transferring the sialic acid from the
activated sugar donor CMP-Neu5Ac to different sugar acceptors
(Table 1). Sialyltransferases normally locate at the Golgi apparatus
as integral membrane proteins adding sialic acids to glycocon-
jugates during their synthesis. However, some sialyltransferases
are also expressed as soluble enzymes (59) and sialyltransferase
activity at plasma membrane has been reported in immune cells
(54). Each sialyltransferase presents high selectivity toward its
acceptor substrate. In vivo, competition between other sialyltrans-
ferases and glycosyltransferases’ common substrates is observed
and, as a result, the cell’s sialylation status is the dynamic sum
of transferase activities, Golgi localization, and concentration
of activated sugar donors. Sialyltransferases depending on their
specificities, can establish α2,3-, α2,6-, α2,8-linkages and can be
organized in four families depending on linkage specificity and
acceptor substrate: the ST3Gal family, catalyzing the addition
of sialic acid to a terminal galactose of O-linked glycans and
glycolipids in an α2,3-linkage; the ST6Gal family, α2,6-linking
sialic acids to galactose residues of N -glycans; the ST8Sia fam-
ily, the only known sialyltransferases promoting the linkage to
another sialic acid residue in N - or O-glycans, in a α2,8-bond;
and, finally, the ST6GalNAc family, adding sialic acid to terminal
N -acetylgalactosamine (GalNAc) residues of glycoproteins and
glycolipids, in an α2,6-linkage (60). Thus, on the cell surface, sialic
acid residues can be present in N - and O-glycans in glycoproteins,
as well as in gangliosides, i.e., a glycolipid containing one or more
residues of sialic acid.
The overall sialic acid content of a cell is also regulated by the
removal of sialic acid residues, catalyzed by the sialidase enzymes.
Four known enzymes fit into this family, also known as the Neu-
raminidase family: Neu1, Neu2, Neu3, and Neu4. These sialidases
are variedly distributed, with Neu1 located at the lysosomes and
also expressed on the surface of diverse types of cells, Neu2 at
the cytosol, Neu3 integrated in the cell membrane, and Neu4
being an intracellular protein. They are all exoglycosidases, i.e.,
they cleave terminal sialic acids, but have different substrate speci-
ficities: Neu1, Neu2, and Neu4 remove sialic acid residues from
glycoproteins, Neu2 and Neu4 also cleaves sialic acids from gly-
colipids, and Neu3 preferentially hydrolyzes gangliosides. A list
of human sialyltransferases and sialidases, their expression pat-
terns in DCs, and their preferred acceptor and donor substrates, is
shown in Table 1.
SIALYLATION AND MODULATION OF THE IMMUNE
RESPONSE
The terminal position occupied by sialic acids on membrane and
extracellular glycans puts them on the frontline during leuko-
cyte communication and overall immune response. Sialic acids,
on an immune perspective, can function in two (seemingly con-
tradictory) major ways: as biological masks and as recognizable
cell patterns (63). In the former way, sialic acid helps shield host
cells from pathogen recognition. It also prevents autoimmune
responses, by preventing complement deposition over cell surface.
Furthermore, it was reported that, during acute phase inflam-
mation, both soluble and cell surface sialic acid is increased, as
a consequence of the increase in soluble and circulatory forms
of sialyltransferases. Higher sialic acid is thus part of the acute
phase response and it seems to protect cells against pathogens, and
also helping the immune system distinguishing “self” from “non-
self” antigens (64). ST6Gal-I is an example of sialyltransferase
whose soluble expression is upregulated during inflammation and
its expression has been used by some authors as a serological
clinical marker for inflammation (65–67). Non-sialylated glycans
are recognized by specific lectins, and the addition of sialic acid
to its terminal position may blocklectin binding. As an exam-
ple, the presence of α2,6-linked sialic acids on N -glycans blocks
recognition by galectins (68), a family of β-galactoside-binding
lectins that regulate diverse cell behaviors, such as cell adhesion,
migration, proliferation, differentiation, transformation, apopto-
sis, angiogenesis, and immune responses (69–73). However, sialic
acid masking can also be used by pathogens, as a mimicry tactic in
order to evade the immune system. This is the case of some Try-
panosoma spp. that have mutated ST3Gal sialyltransferases that
act as trans-sialidases, transferring the host’s sialic acid to coat
themselves in order to evade host recognition (74, 75).
Opposed to the asialylated-glycan recognition, sialic acids
can be recognized by several cell surface receptors, such as the
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Table 1 | Human sialyltransferases and sialidases.
Preferred saccharide substrate Glycan specificity Dendritic cell expression (cell status)
SIALYLTRANSFERASE
ST3Gal-I Galβ1,3GalNAc O-glycan Yes
ST3Gal-II Galβ1,3GalNAc O-glycan Yes (mature)
ST3Gal-III Galβ1,3(4)GlcNAc O-glycan, N -glycan Yes (mature)
ST3Gal-IV Galβ1,4(3)GlcNAc N -glycan, O-glycan Yes (mature)
ST3Gal-V Galβ1,4Glc-ceramide Glycolipid Yes
ST3Gal-VI Galβ1,4GlcNAc N -glycan Yes
ST6Gal-I Galβ1,4GlcNAc N -glycan Yes
ST6Gal-II Galβ1,4GlcNAc N -glycan No
ST6GalNAc-I GalNAcα1,O-Ser/Thr O-glycan No
Galβ1,3GalNAcα1, O-Ser/Thr
ST6GalNAc-II Galβ1,3GalNAcα1, O-Ser/Thr O-glycans Yes
ST6GalNAc-III Siaα2,3Galβ1,3GalNAc O-glycan Yes (?)
ST6GalNAc-IV Siaα2,3Galβ1,3GalNAc O-glycan Yes
ST6GalNAc-V GM1b Glycolipid No
ST6GalNAc-VI All α-series gangliosides Glycolipid Yes
ST8Sia-I Siaα2,3Galβ1,4Glc-ceramide Glycolipid No
ST8Sia-II Siaα2,3Galβ1,4GlcNAc N -glycan on NCAM No
ST8Sia-III Siaα2,3Galβ1,4GlcNAc N -glycan on NCAM No
ST8Sia-IV (Sialα2,8)nSiaα2,3Galβ1-R N -glycan on NCAM Yes
ST8Sia-V GM1b, GT1b, GD1a, GD3 Glycolipid No
ST8Sia-VI Siaα2,3(6)Gal Sialic acid on O-glycan Unknown
SIALIDASES
Neu1 Siaα2,3 Oligosaccharides Yes
Siaα2,6 Glycopeptides
Neu2 Siaα2,3 Oligosaccharides No
Siaα2,6 Glycopeptides
Gangliosides
Neu3 Siaα2,3 Gangliosides Yes (mature)
Siaα2,6
Neu4 Siaα2,3 Oligosaccharides Yes
Siaα2,6 Glycopeptides including mucins
Gangliosides
Preferred substrates for each enzyme and expression pattern in human dendritic cells are indicated. Data was based on (2, 4, 61, 62).
? stands for “unknown” regarding the cell status (whether mature or immature).
previously mentioned CLRs and Siglecs (41, 76). Siglecs are sialic
acid-recognizing proteins that, albeit structurally similar, are com-
monly organized in two categories: (i) one comprises the CD22
family [including CD22 (or Siglec-2), sialoadhesin (or Siglec-1),
myelin-associated glycoprotein (MAG or Siglec-4), and Siglec-
15]; and (ii) the CD33-related family comprising CD33 (or Siglec
3), Siglec-5, -11, -14, and -16 in humans, all chiefly expressed
in myeloid and lymphoid cells (63, 77). Siglecs recognize and
bind ligands present not only in other cells (viz., in trans) but
also on the same cell (in cis). Many Siglecs present one or two
intracellular immunoreceptor tyrosine-based inhibitory motifs
(ITIMs), classically described as being involved in signaling to
regulation-inducing pathways,or intracellular tyrosine-based acti-
vation motifs (ITAMs), involved in the initiation of activation sig-
naling pathways. Hence, Siglecs have a decisive role in regulating,
positively or negatively, immune responses such as inflammation
or tissue damage by actively discriminating between self-associated
molecular patterns (SAMPs) and PAMPs (41, 63, 78, 79).
Studies using mice deficient for selected α2,3- and α2,6-
sialyltransferases have provided evidence confirming the impor-
tance of sialic acid in immune processes (80–82). ST6Gal-I KO
mice were reported as presenting impaired humoral immune
response, namely, by reduced concentration levels of circulat-
ing and surface IgM, impaired B cell proliferation in response
to various activation signals and impaired antibody production
following contact with antigens (80). CD22, one of the first
described Siglecs (83), was later shown to recognize ST6Gal-I-
mediated glycans, functionally regulating several B cell functions
and survival mechanisms (84). Other ST6Gal-I KO mice studies
have also revealed that soluble forms of ST6Gal-I have a rele-
vant role in myelopoiesis during acute inflammation, namely, by
limiting it, thus avoiding uncontrolled excessive neutrophilic and
eosinophilic inflammatory responses (59, 85, 86). Using ST3Gal-
I KO mice, on the other hand, it has been shown that α2,3-
sialylated O-glycans are required for CD8+ T cell homeostasis
and survival (82).
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These are only few examples on how sialic acids influence
immune-relevant processes. Other examples include roles in host-
pathogen interactions, regulation/modulation of the acute phase
response and influence in the progression and differentiation of
human malignancies.
DENDRITIC CELLS AND SIALIC ACID
As above mentioned, DCs play a role of enormous relevance in
the immune system. Ever since Dr. Steinman and co-workers first
described these cells (87–91), there has been an effort to fully
characterize their immunobiology, and as part of those efforts,
the relevance that glycosylation may have on it. The characteriza-
tion of the DC’s “glycome” (“sialome” included) and its functional
impact on the DCs immunobiology and, of course, on the immune
system has been a work in progress. There are many questions still
open, with many potential clinical applications.
SIALYLATION IN DENDRITIC CELLS
In human DCs, the sialylation profile of inflammatory DCs has
been the most studied. This comes as the result of two factors: first,
they are the most frequent population of DCs and, second, in more
practical terms, they are the easiest subset to obtain in vitro with
human moDCs being a widely used human conventional migra-
tory and inflammatory DC model. Other vertebrate DC models
rely on the obtainment of DCs by differentiation of bone marrow
extracts or, more specifically, CD34+ hematopoietic precursors
myeloid lineage (92).
Immature moDCs present a high sialylation content, namely
α2,3- and α2,6-sialylated glycoproteins, when compared to its
monocyte precursors (4, 93). This has been reported by dif-
ferent teams that used plant lectins from Sambucus nigra and
Maackia amurensis, preferably recognizing α2,6-linked sialic
acid linked to lactosamine (Neu5Acα2,6Galβ1,4GlcNAc-) in
N -glycans and α2,3-linked sialic acid linked to lactosamine
(Neu5Acα2,6Galβ1,4GlcNAc-), respectively.
Quantitative Real-Time PCR and microarray analysis has
shown that both sialyltransferases and sialidases undergo signif-
icant gene expression variation during differentiation and matu-
ration (4, 62, 93, 94). In particular, a significant upregulation of
the ST3Gal-I and ST6Gal-I genes occurs during moDCs’ differ-
entiation that correlates with an increase of enzymatic activity
by these two enzymes. Increased phenotypic change in α2,3-
and α2,6-sialylation (4) during myeloid lineage-committed dif-
ferentiation indicates these two sialyltransferases as the major
contributors to the biosynthesis of α2,3- and α2,6-linked sialic
acid-containing glycan structures specific for moDCs, with poten-
tial functional relevance. There are, however, other potentially
relevant sialyltransferases that should not be discarded, such as
ST3Gal-IV and -VI, being described as essential for the synthesis
of the adhesion-related sialyl-Lewis x (sLex) antigens. Regarding
sialidases, modulation during moDCs’ differentiation is similarly
observed, with Neu1 and Neu3 being significantly upregulated
during this process (62). Maturation of moDCs leads to an
increase of α2,3-sialylation and a decrease of α2,6-sialylation (2,
4, 93) although the reported variations are stimulus-dependent
processes, and correlated with the sialyltransferases and sialidases
activity.
While the functional impact of these observed sialic acid
changes has to be further elucidated, there is already some evi-
dence that these variations are biologically relevant, as it will be
discussed further on in this review.
SIALIC ACID-RECOGNIZING DENDRITIC CELL RECEPTORS
Sialic acid-containing glycans expressed by DCs are the target of
receptors, such as Siglecs, being the largest represented family.
Recognition of DC sialylated glycans has functional implications:
examples include a recognition mechanism of high α2,6-sialic acid
content of immature and tolerogenic DCs by inhibitory Siglecs
expressed by effector T cells as a host-tolerance-inducing mecha-
nism (93), or the observed increased binding of Siglecs-1, -2, and
-7 correlating with the higher sialic acid content of mature DCs
(2). All this gathered evidence point to an even more promis-
ing, relevant role of Siglec-mediated immunobiological processes
involving DCs and other leukocytes, but still to be unraveled and
requiring, thus, further studies.
Besides being recognized by Siglecs through their expression of
glycans, DCs express themselves Siglecs enabling them to also rec-
ognize sialylated structures. MoDCs and blood-circulating DCs
[namely pDCs, CD1a+, and CD141+ DCs (95)] express Siglec-
1, -2, -3, -5, -7, -9, -10, -14, and -15 (2, 43, 78, 96), while pDCs
have a more restricted pattern and apparently only express Siglec-5
(43). Siglecs, with the exception of Siglec-14 and -15, expressed by
DCs present ITIM motifs in their cytosolic portion and are there-
fore mainly involved in inhibiting activation signals and have an
immunoregulatory function (40, 41).
The concentration of sialic acids on surfaces of human cells
is very high; for example, Stamatos and colleagues estimated that
DCs had 8.9 nM per 5× 106 cells, which correspond to nearly 1018
sialic acid molecules per cell (62).
Therefore, it is possible that the majority of Siglecs expressed
at DC surface bind in cis, i.e., to sialic acids at their own cell
surface. The cis interaction will have primacy over the trans
interactions, the only exception being sialoadhesin, which has an
extended structure, projecting their binding site away from plasma
membrane and being therefore involved in trans interactions (97).
Siglec interactions in cis can be released by sialidase activity,
either extrinsic for instance from pathogens or intrinsically due
to the activity of endogenous sialidases (40, 98). Since DCs ulti-
mate function is to immunomodulate T cells and (to some extent)
B cells, Siglecs potentially play a largely relevant role in host-
tolerance mechanisms (2, 43, 99). Chen and co-workers reported
Siglec-10 as involved in helping distinguish TLR-recognized
danger-associated molecular patterns (DAMPs) – generated dur-
ing cell/tissue damage or even regular cell lifecycle – from PAMPs,
thus controlling inflammation (100). There are known exam-
ples of T cell activation where DC Siglecs have a relevant role
in inducing Th1 and Th2 responses, as is the case of DC Siglecs-1
and -7 trans recognition of α2,3-sialic acids and α2,8-polisialic
acids, respectively, in mimicked GM1a and GD1a (Siglec-1 recog-
nized) and GD1c (Siglec-7 recognition) gangliosides included in
Campylobacter jejuni’s LPSs (101).
CD33-related Siglecs can function as endocytic receptors that
are important in the clearance of sialylated antigens. On the other
hand, many pathogens are able to express appropriate sialic acids
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themselves (102–105). Pathogen’s sialic acids may interfere with
DC functions such as endocytosis (43, 106) thus helping DCs to
internalize and further present pathogen’s antigens. This, however,
may also open an opportunity window for pathogens to modu-
late DCs’ immune functions (by binding to immunoregulating
Siglecs) or even use DCs as vectors (i.e.,“Trojan horses”) for infec-
tion of other immune system cells, such as HIV using Siglec-1 as
a gateway-receptor for DC entry and posterior transmission to
CD4+ T cells (107). However, a safety mechanism may be present:
Siglec-15 can act as an activation receptor balancing the negative
signaling triggered after recognition of sialylated pathogens (viz.,
enveloped viruses) through inhibitory Siglecs (78).
DENDRITIC CELL SIALYLATION AND ENDOCYTOSIS
The sialic acid’s role on endocytosis has long been studied on the
perspective of the pathogen. Besides the already referred trans-
sialidase bearing T. cruzi parasite, it is also known that several
bacteria developed sialic acid-masking mechanisms in order to
escape immune surveillance and/or response (108). Recent dis-
coveries, however, hinted that sialic acid’s role in these immune
processes goes far beyond than “just” being an antigen, with
a functional impact on the innate immune phase cells as well,
like DCs.
As previously mentioned DCs are functionally well prepared to
endocytose pathogens, in order to process and present them to the
adaptive immune response cells (20, 109, 110). Using two different
approaches – sialidase treatment of moDCs and bone marrow-
derived DCs (BMDCs) from sialyltransferase KO mice, it has been
determined the functional impact of sialic acid on macropinocy-
tosis and phagocytosis. Asialylated DCs presented significantly
reduced ovalbumin-macropinocytosis but increased phagocytosis
levels (111). Similar results having been obtained using BMDCs
from ST6Gal-I and ST3Gal-I sialyltransferase-deficient mice (3).
Sialic acid removal (or absence in BMDCs) has a positive impact
over the DC maturation process, leading to higher expression of
maturation markers. Hence, this effect should account for the
observed reduction of macropinocytosis levels, since matured DCs
tend to have decreased endocytosis ability (112). The observed
increase in phagocytosis in asialylated immature and mature
DCs (111) seems, therefore, to oppose the endocytosis reduction
induced by maturation. It is documented, however, that mature
DCs may continuously uptake antigens by phagocytosis and
receptor-mediated endocytosis, even if always described in lower
levels than immature DCs (110, 113). As no studies have been per-
formed from a sialic acid point of view, this can account for novel,
groundbreaking evidence adding to the well-established concepts
of endocytosis. Another piece of this apparent puzzle lies in the DC
cytoskeleton, which has to be adjusted to perform cellular exten-
sions needed for phagocytosis. After sialidase treatment of DCs, a
cytoskeleton disorganization is observed. In addition, the activity
of two Rho GTPases – Rac1 and Cdc42 – that regulate, among
other processes, the actin-dependent events of macropinocytosis
and phagocytosis (19, 112, 114–116) are downregulated, after sial-
idase treatment. This may justify the cytoskeleton disorganization
and decreased macropinocytosis.
Hence, the fact that sialidase treatment accounts for the signif-
icant E. coli phagocytosis enhancement, in both sialidase-treated
immature and mature DCs, is a process unrelated to maturation.
Interestingly, the effect on phagocytosis seems to depend on the
presence, in trans, of bacterial sialic acid (111), adding a potential
involvement of Siglecs. Hence, sialidase treatment would release
DCs’ Siglecs from in cis ligands, making them available to bind to
ligands in trans, such as sialic acid-containing glycans present in
the E. coli cell wall. However further investigations are still needed
to elucidate the underlying mechanisms.
Sialidase-induced activation of receptors is not a novel phe-
nomenon. Receptors like TLR-4 are known to depend on the
activity of membrane sialidase prior to LPS-induced activation:
in mice, DC phagocytosis is activated by desialylation of surface
receptors (62, 117, 118). This evidence is in line with the already
mentioned increased expression of sialidases, such as Neu1 during
DCs differentiation and maturation (117). Furthermore, physio-
logically, cell surface sialic acid content is not exclusively cleaved
by endogenous sialidases, since exogenous sialidase sources are
also released by pathogenic bacteria or virus during the course
of an infection. In the mouse model, it was reported that Neu1-
induced desialylation activates phagocytosis by macrophages and
DCs (118). Also, cell surface desialylation by influenza virus sial-
idase stimulates the internalization of target virus by infected
mouse macrophages (119).
Siglecs and TLRs fit perfectly in the recent model presented
by Cabral and collaborators showing that sialidase treatment of
DCs favors phagocytosis (111). Since they are receptors with
both strong activating- and suppressive-inducing properties, with
known roles in regulating immune responses and with the poten-
tial of becoming active after sialic acid removal by sialidases, they
are also likely to account for the observed upregulation of both
pro- and anti-inflammatory cytokines (111). Nevertheless, the
referred receptor families may not be the only receptors affected
by sialidase treatment in DCs as novel glycan-protein interactions
are continuously being revealed, but further studies are in order to
better elucidate the role of sialic acid in endocytosis.
SIALYLATION AND DENDRITIC CELL MIGRATION
Dendritic cell migration includes both DC recruitment to non-
lymphoid tissue and homing to lymphoid organs.
When located within tissues, DCs may respond to pro-
inflammatory cytokines and pathogens, which trigger maturation
and DCs then migrate to lymphoid tissues via afferent lymphatic
vessels, wherein they activate antigen-responsive T cells. Immature
and mature DCs may also enter the blood and from there dissem-
inate to non-lymphoid and lymphoid organs, thereafter returning
to blood, thus undergoing cycles of recirculation. Therefore DCs
have complex trafficking routes, allowing for dynamic reassort-
ment of DCs, making the most of their capacity to uptake antigens
and to encounter T cells to present antigens and activate them.
While, generally, the migratory processes are based upon mech-
anisms like adhesion and chemotaxis, some processes still show
their own particularities. The extravasation of blood DCs to any
tissue involves DC adhesion to endothelium and is dependent
of selectin interactions with sialofucosylated glycans. The role of
certain sialylated glycans as selectin ligands is one of the most
recognized functions of sialic acid in the context of leukocyte
recruitment (120).
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Selectins are CLRs expressed by platelets, endothelium, or
leukocytes, hence taking their name: P-, E-, or L-selectins, although
endothelial cells also express P-selectins.
All selectins recognize the sialic acid and fucose (Fuc) contain-
ing tetrasaccharide, where sLex (Neu5Acα2,3Galβ1,4[Fucα1,3]
GlcNAc-) is the major prototype. Selectin ligands are expressed in
most circulating immune cells and some endothelial cells during
inflammation. They mediates essentially the rolling and tether-
ing phase of cell transmigration over the endothelial cell surface
(121). sLex expression is well characterized in neutrophils and
lymphocytes (76, 122) but only relatively approached in DC (123–
126). Recently, it was found that moDCs also express functional
selectin ligands, based on their observations of moDC tethering
and rolling over a P-, E-, and L-selectin immobilized surface (126).
They observed decreasing tethering affinities (by decreasing order)
toward P-, E-, and L-selectin, with similar lower rolling velocity on
P- and E-selectins and the largest rolling velocity observed over
L-selectins. These findings were in line with other studies using
blood DCs and CD34+-derived DCs (125, 127). Furthermore, the
use of anti-sLex antibodies on the rolling studies resulted in a sig-
nificant binding inhibition, definitely proving that sLex mediates
the moDCs-selectin binding (126).
In order to properly function as a selectin ligand, sLex must
be expressed in carrier glycoproteins or glycolipids (128, 129).
The only described sLex carrier-protein described in moDCs is
the P-selectin glycoprotein ligand-1 (PSGL-1) (123), a mucin-
like glycoprotein, present in the microvilli of most leukocytes
(130, 131) (Figure 2, “Cell adhesion” feature). In DCs, sLex-
decorating PSGL-1 is the solely ligand for P-selectin, with sig-
nificant less affinity toward L-selectin and being indifferent for
E-selectin binding (126).
Nevertheless, sialic acids also participate in the chemokine
receptor-mediated firm arrest, as well as in β1 integrins function
(132–134). There is also evidence concerning the chemokine-
mediated migration to the lymph nodes. It was recently reported
that ST8Sia-4-dependent polysialylation of neuropilin-2 seems to
be relevant for chemokine-driven migration toward lymph nodes
(135). Other report claims that ST3Gal-IV is not relevant for
chemokine-dependent DC homing, in the mouse model (120),
but, interestingly, our team’s preliminary studies using ST6Gal-
I-deficient mice have shown impaired DC migration toward
draining lymph nodes, suggesting a previously unknown role for
α2,6-sialylated N -glycans in DC homing.
Dendritic cell mobility is a crucial step still needing to be better
elucidated. Most of the clinically efficacy of DC immunotherapy
relies on the migration ability of these cells. In ex vivo generated
DC vaccines, it is estimated that only 1–2% of total adminis-
tered DCs reach secondary lymphatic organs (136). Therefore
the majority of ex vivo generated DCs are inefficient because
they do not meet T cells. Thus, understanding DC migration
should be regarded as important to find means to improve DC
immunotherapy.
SIALIC ACID IN DENDRITIC CELL-T CELL INTERACTIONS
The ultimate function of DC immunobiology is the DC-T cell
interaction, whereupon DCs present the uptaken, processed anti-
gens to T cells, thus eliciting a specific, long-lasting immune
response. Since immunological synapses between these two cells
involve glycoprotein receptor-mediated process, it is, thusly, poten-
tially influenced by sialic acid.
Dendritic cells’ sialic acid-containing glycans have been shown
to negatively influence T cell priming, most likely by interference
on MHC-mediated antigen presentation and co-stimulation (137,
138). In line with these findings, sialidase-treated moDCs were
able to prime T cells and induce proliferation more efficiently
than fully sialylated moDCs (3, 111). This effect could be attribut-
able to the increased maturation by sialidase-treated moDCs (3).
However, one should not discard a synergistic effect with enhanced
protein–protein interaction due to the absence of the negatively
charged sialic acid (137), leading to enhanced inter cellular interac-
tions. The verified upregulation of a set of pro-inflammatory, Th1
profile-inducing cytokine expression (viz., IL-1α, -6, -12,and TNF-
α) in sialidase-treated moDCs (with subsequent IFN-γ secretion)
could also account for the observed increased priming.
Reinforcing these results,others have observed that endogenous
sialidase activity also promotes cytokine production by moDCs
and this has been attributable to the action of Neu3 upregula-
tion during moDC differentiation (62). Interestingly, tolerogenic,
immature moDCs present high sialic acid content, as well as reg-
ulatory T cells. Thus it has been hypothesized that, host-tolerance
induction by DCs could be a Siglec-mediated process (93).
Taken together, this evidence reminds that DC sialylation has
implications in the T cell interaction and it is likely to twist
the immunogenic/tolerogenic balance. Thus sialylation should
be considered to fine tune DC-based therapy either pathology-
treating or tolerance-inducing.
DENDRITIC CELL GLYCAN RECOGNITION OF TUMORS
Dendritic cells functions also include specific identification of
tumor cells and presentation of tumor antigens to T cells. One
of the mechanisms for tumor cells recognition is through the
binding of cells surface receptors to tumor-specific antigen (TSA),
with an almost exclusive tumor expression and tumor-associated
antigens (TAAs), normally expressed on the cells but of aberrant
expression on tumor cells (139). Upon recognition, these antigens
normally elicit a maturation response on DCs but the immune
potency depends on many factors, including the antigen. Tumors
have, however, several evasion strategies from immune responses,
achieving this by creating a tolerance-inducing microenviron-
ment, secretion of inhibitory factors, and activation of immuno-
suppressant intracellular pathways in the immune cells (140–142).
DCs present certain flaws in their antigen-presenting strategy
that tumor cells take advantage of in order to create defective
T cell responses, thus creating problems in generating effective
anti-tumoral solutions (142, 143).
Aberrant glycosylation is a hallmark of cancer cells and aber-
rant glycosylated proteins can be shed into the body fluids of
the patients (serum, urine, pleural effusions, etc.). This altered
glycosylation pattern in tumor cells includes either a loss or a
gain of expression of certain glycan structures, the appearance
of truncated structures, as well as of novel structures. Upregu-
lation and/or downregulation of specific glycosyltransferases is
often responsible for these changes. Tumor-associated carbohy-
drate (TAC) structures allow tumor cells to invade and metastasize
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FIGURE 2 | General overview of the dendritic cell functions
modulated by sialylation. Sialic acid-containing glycans actively
participate and modulate processes like: cell adhesion during migration
and homing; or in “de facto” immune processes such as tumor cell
recognition and microbial recognition, overall modulating the immune
response/tolerance balance.
or to evade the immune system. Immature and/or tolerogenic
DCs can migrate to the rapidly growing tumor microenviron-
ment, thus eliciting immune tolerance in several ways, such
as T cell deletion, anergy, and Treg activation (142–145). The
tolerogenic profile depends on the DCs recognition and bind-
ing to TAC. However, how DCs recognize the tumor cells and
in particular the TAC are not fully disclosed. The few avail-
able studies point, so far, to the CLRs, MGL-1, and DC-SIGN
receptors as being relevant in tumor recognition and undesired
tolerance induction (37, 146): the former is highly expressed
in immature, tolerogenic DCs, and shown to interact with the
tumor-associated Tn antigen-bearing forms of MUC1 (147); the
latter is also expressed by immature DCs and recognizes Lex
and Lewis Y (Ley) glycoantigens in a carcinoembryonic antigen-
context expressed in colorectal carcinoma. Besides these recep-
tors, the observed involvement of DCs’ Siglecs (such as Siglec-3
and -9) could help justifying the frequent tolerance-induction
mechanisms: by recognizing overexpressed sialylated antigens at
the tumor microenvironment (e.g., sialyl T and sLea expressed
on mucins), these receptors could send inhibitory intracellular
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signals from their ITIM motifs thus preventing DCs from
differentiating (by inducing apoptosis of their precursors) or mat-
urating, keeping them in a tolerance-inducing state with concomi-
tant upregulated anti-inflammatory cytokine expression, down-
regulated pro-inflammatory cytokine expression, and reduced
antigen-presenting capability (148–150).
It is now evident that TAC and in particular, sialic acid expres-
sion influences tumor progression. DCs become tolerogenic after
recognition of TAC (including glycan-bearing/glycosylated TAC),
favoring tumor progression and being generally associated with
bad prognosis. The collected evidence regarding the glycan influ-
ence on anti-carcinogenic immune processes should be, there-
fore, seriously considered whenever DC-based immunotherapies
against specific malignancies are available.
CONCLUDING REMARKS
The weight of glycosylation and, in particular, sialic acid in bio-
logical processes is being increasingly acknowledged. Being at
the terminal position of many glycans, it plays an essential role
in modulating many of the DC functions. In human DCs, the
majority of studies to date have focused on moDCs and only
scattered and very scarce data was reported regarding other sub-
sets. It would be extremely important to study these and other
immune mechanisms from the newly identified subsets’ perspec-
tive and to complement those studies using mouse DCs other than
the traditionally (myeloid) BMDCs. Being known that different
subsets of DCs have different functions/affinities toward differ-
ent pathogens/tissues (and elicit different responses) it should not
come as a surprise that different subsets could express different
glycans and glycan-recognizing receptors, having thus different
underlying mechanisms and eliciting different immune responses.
The discovery and accessibility of new, faster, and more precise
glycobiology-related techniques may allow a better understanding
of the role of sialylation and glycosylation in DCs. The prob-
lem that poses glycobiologists, and immunologists in particular, is
trying to add a new perspective and knowledge, in the same mag-
nitude, to the amount of knowledge that proteomics and genetics
have gathered the last 30 or 40 years, in a short amount of time.
That premise is getting growingly important every time a relevant
role for glyco-based phenomenon is identified. Our hope, with
this review is that we contributed a little bit more to put the spot-
light on Glycoimmunology and encourage further investigations
on this subject.
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